En Es
Categories

Industry News

Abbott Closes Acquisition of Alere

By Labmedica International staff writers
11 Oct 2017

Image: Abbott has closed the acquisition of Alere (Photo courtesy of iStock).Abbott (?Lake Bluff, IL; USA) has closed the acquisition of Alere, Inc. (Waltham, MA; USA), following the receipt of all regulatory clearances required for the closing.

Abbott is a global healthcare company with a portfolio of offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, while Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. The transaction makes Abbott the global leader in point of care testing and further strengthens the company's diagnostics presence.

Point of care testing is a USD 7 billion segment of the USD 50 billion in vitro diagnostics market and is growing rapidly as a number of health care systems are increasing their reliance on these technologies to inform patient care decisions with easy-to-use tests that provide speed and accuracy, particularly in the outpatient setting. With the addition of Alere, Abbott has approximately USD 7 billion in diagnostics sales worldwide, including about USD 2.5 billion in point of care testing.

“Creating the world's leading point of care business will help Abbott meet the growing demand for fast, accurate and actionable information,” said Brian Blaser, executive vice president, Diagnostics Products, Abbott. “Combined with Abbott's existing point of care business and its leading hand-held platform, i-STAT, we now have the broadest point of care testing portfolio to help improve care for patients in more parts of the world.”



E-mail Print
FaceBook Twitter Google+ Linked in

More articles about ABBOTT

13 Dec 2016
Abbott Seeks to Terminate Alere Acquisition
Abbott Laboratories has filed a complaint in the Delaware Court of Chancery seeking termination of its proposed acquisition of Alere, citing material adverse events after both the companies had entered into a merger agreement on January 30, 2016.
Read More

Additional news

21 Feb 2018
Stroke Detection Software Receives FDA Clearance
The US FDA has approved a new clinical decision support software that notifies neurologists about a potential stroke in their patients by analyzing computed tomography (CT) results. The tool named Contact has been developed by Viz.ai, a direct-to-intervention healthcare company that uses artificial intelligence (AI) and deep learning algorithms to analyze medical data and improve medical workflow.
Read More
21 Feb 2018
AI in Medical Imaging to Surge in Coming Years
The use of machine learning or artificial intelligence (AI) technology by hospitals and imaging centers is expected to surge by 2020, with its highest application to be in the area of breast imaging.
Read More
21 Feb 2018
New Deep Learning-Based Algorithm Can Assess Breast Density
Researchers from the University of Pittsburgh Medical Center have developed a new deep learning-based algorithm for breast density segmentation and estimation that correlated well with BI-RADS density assessments by radiologists and also outperformed an existing state-of-the-art algorithm.
Read More
13 Feb 2018
QIAGEN Enters into Agreement to Acquire STAT-Dx
QIAGEN N.V. has entered into an agreement to acquire STAT-Dx, a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
Read More
08 Feb 2018
AI Could Learn How to Understand Radiologist Reports
Researchers at the Icahn School of Medicine at Mount Sinai have used machine learning techniques, including natural language processing algorithms, to identify clinical concepts in radiologist reports for computed tomography (CT) scans. The technology marks an important first step in the development of artificial intelligence (AI) that could interpret scans and diagnose conditions.
Read More
08 Feb 2018
AR and VR in Healthcare Market to Reach USD 4.9 Million by 2023
The augmented reality (AR) and virtual reality (VR) in the healthcare market was valued at USD 769.2 million in 2017 and is expected to grow at a CAGR of 36.6% during the forecast period to reach USD 4,997.9 million by 2023. The market growth will be driven by increasing penetration of connected devices in the healthcare sector, rising investment in healthcare AR and VR, and growing need to reduce healthcare costs. However, the lack of competence in the deployment of AR and VR solutions, and lack of expertise among medical practitioners to adopt new technologies are the major restraints for market growth.
Read More
08 Feb 2018
Elekta Collaborates with IBM Watson Health to Bring AI to Oncology
Elekta is collaborating with IBM Watson Health to offer Watson for Oncology with its cancer care solutions. Beginning in early 2018, Elekta will sell Watson for Oncology as a clinical decision support solution, paired within its digital cancer care solutions, including the MOSAIQ Oncology Information System.
Read More
08 Feb 2018
AR System Allows Surgeons to Reconnect Blood Vessels
A team of researchers at Imperial College London at St Mary’s Hospital has demonstrated the use of Microsoft HoloLens headset for performing reconstructive lower limb surgery on patients. The HoloLens is a self-contained computer headset that immerses the wearer in ‘mixed reality’, allowing them to interact with ‘holograms’ which are computer-generated objects made visible through the visor.
Read More
29 Jan 2018
Top Drivers of Global Laboratory Centrifuge Market
The global laboratory centrifuge market is expected to grow steadily at a CAGR of more than 5% during the forecast period 2017-2022, driven mainly by the increasing number of biotechnology and pharmaceutical research studies, growing use of molecular diagnostics in hospitals, and technological advancements.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions